Abstract
Amongst all currently used drugs in the field of cancer therapy, the most prominent group of agents which induce DNA, damage both directly or indirectly. Intuitively DNA should not be a perfect target for relatively unspecific small molecular weight drugs. However, the current understanding is that not damage per se but cellular response to DNA damage induced by antitumor agents is responsible for their specific targeted effect towards cancer cells in comparison to the normal cells. DNA damaging chemotherapeutics include compounds with diferent activities namely: directly or indirectly induce DNA strand breaks, covalently modify DNA bases, change the chromatin structure and topology by inhibiting chromatin-modifying enzymes. In this special issue of Current Medicinal Chemistry entitled....
Current Medicinal Chemistry
Title:Editorial: DNA Damage as a Strategy for Anticancer Chemotherapy
Volume: 24 Issue: 15
Author(s): Maria Bozko, Andrzej Bozko, Tim Scholta, Nisar P. Malek and Przemyslaw Bozko*
Affiliation:
- Department of Internal Medicine I, Eberhard Karls University Tubingen Tubingen,Germany
Abstract: Amongst all currently used drugs in the field of cancer therapy, the most prominent group of agents which induce DNA, damage both directly or indirectly. Intuitively DNA should not be a perfect target for relatively unspecific small molecular weight drugs. However, the current understanding is that not damage per se but cellular response to DNA damage induced by antitumor agents is responsible for their specific targeted effect towards cancer cells in comparison to the normal cells. DNA damaging chemotherapeutics include compounds with diferent activities namely: directly or indirectly induce DNA strand breaks, covalently modify DNA bases, change the chromatin structure and topology by inhibiting chromatin-modifying enzymes. In this special issue of Current Medicinal Chemistry entitled....
Export Options
About this article
Cite this article as:
Bozko Maria , Bozko Andrzej , Scholta Tim , Malek P. Nisar and Bozko Przemyslaw *, Editorial: DNA Damage as a Strategy for Anticancer Chemotherapy, Current Medicinal Chemistry 2017; 24 (15) . https://dx.doi.org/10.2174/092986732415170630115722
DOI https://dx.doi.org/10.2174/092986732415170630115722 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticancer α-Helical Peptides and Structure / Function Relationships Underpinning Their Interactions with Tumour Cell Membranes
Current Protein & Peptide Science Investigation of the Metal Bonding Properties of Some ARA-II Compounds Using Spectrofluorimetric Method
Current Drug Therapy Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (γ) Agonist
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Expanding the Therapeutic Potential of Statins by Means of Nanotechnology Enabled Drug Delivery Systems
Current Topics in Medicinal Chemistry Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Role of Infrared Spectroscopy and Imaging in Cancer Diagnosis
Current Medicinal Chemistry Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells
Current Cancer Drug Targets Substance P Prevents Vascular Endothelial Dysfunction in Metastatic Breast Carcinoma
Protein & Peptide Letters Postoperative Radiotherapy After Radical Prostatectomy: Adjuvant or Salvage?
Current Cancer Therapy Reviews Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy
Current Radiopharmaceuticals MicroRNA and HER2-overexpressing Cancer
MicroRNA The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Concurrent Administration of Rituximab and CHOP Chemotherapeutic Agents for Outpatients with CD20-positive Lymphoma
Anti-Cancer Agents in Medicinal Chemistry The Role of the Gastrointestinal Microbiota in Colorectal Cancer
Current Pharmaceutical Design Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Genistein Decreases APP/tau Phosphorylation and Ameliorates Aβ Overproduction Through Inhibiting CIP2A
Current Alzheimer Research